Mesoblast up on deal for late-stage trial of GvHD therapy

Mesoblast

22/11/2023 12:54

** U.S.-listed shares of Australia-based Mesoblast  MESO.O 
 MSB.AX  up 5.8% at $1.28 premarket
    ** Regenerative medicine co strikes partnership with U.S.
govt-funded firm to design late-stage trial for its lead therapy
candidate, Ryoncil, for severe form of graft-versus-host disease
(GvHD) in patients that do show improvement on steroids 
    ** GvHD is complication after stem cell or bone marrow
transplant in which newly generated immune cells attack
recipient's body cells, which can be life-threatening
     ** FDA says there are no available therapies for this form
of disease
    ** 1 of 5 brokerages rate the stock "buy", 3 "hold" and 1
"sell"; their median PT is $2
    ** Up to Tuesday's close, stock down 58.4% YTD 
 

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))